Free Trial

CervoMed (CRVO) Stock Price, News & Analysis

CervoMed logo
$2.33 +0.10 (+4.48%)
As of 01/3/2025 05:39 PM Eastern

About CervoMed Stock (NASDAQ:CRVO)

Key Stats

Today's Range
$2.24
$2.43
50-Day Range
$1.90
$14.08
52-Week Range
$1.80
$26.38
Volume
276,492 shs
Average Volume
257,646 shs
Market Capitalization
$14.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$42.00
Consensus Rating
Hold

Company Overview

CervoMed Inc., a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery. The company also develops EIP200 for central nervous system which is in preclinical trials. CervoMed Inc. was founded in 2010 and is headquartered in Boston, Massachusetts.

CervoMed Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
60th Percentile Overall Score

CRVO MarketRank™: 

CervoMed scored higher than 60% of companies evaluated by MarketBeat, and ranked 455th out of 952 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    CervoMed has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 3 buy ratings, 4 hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    CervoMed has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about CervoMed's stock forecast and price target.
  • Earnings Growth

    Earnings for CervoMed are expected to decrease in the coming year, from ($1.77) to ($1.82) per share.

  • Price to Book Value per Share Ratio

    CervoMed has a P/B Ratio of 1.79. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    48.41% of the float of CervoMed has been sold short.
  • Short Interest Ratio / Days to Cover

    CervoMed has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in CervoMed has recently increased by 34.90%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    CervoMed does not currently pay a dividend.

  • Dividend Growth

    CervoMed does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    48.41% of the float of CervoMed has been sold short.
  • Short Interest Ratio / Days to Cover

    CervoMed has a short interest ratio ("days to cover") of 6.9.
  • Change versus previous month

    Short interest in CervoMed has recently increased by 34.90%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    CervoMed has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.87 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for CervoMed this week, compared to 2 articles on an average week.
  • Search Interest

    9 people have searched for CRVO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added CervoMed to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, CervoMed insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    36.30% of the stock of CervoMed is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 25.15% of the stock of CervoMed is held by institutions.

  • Read more about CervoMed's insider trading history.
Receive CRVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CervoMed and its competitors with MarketBeat's FREE daily newsletter.

CRVO Stock News Headlines

CervoMed downgraded to Neutral from Buy at H.C. Wainwright
URGENT: This Altcoin Opportunity Won’t Wait – Act Now
Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.
CervoMed (CRVO) was downgraded to a Hold Rating at H.C. Wainwright
CervoMed announces inducement grants under Nasdaq lisitng rule
CervoMed price target lowered to $12 from $65 at Canaccord
See More Headlines

CRVO Stock Analysis - Frequently Asked Questions

CervoMed's stock was trading at $2.34 on January 1st, 2025. Since then, CRVO shares have decreased by 0.4% and is now trading at $2.33.
View the best growth stocks for 2025 here
.

CervoMed Inc. (NASDAQ:CRVO) released its quarterly earnings data on Tuesday, November, 12th. The company reported ($0.55) EPS for the quarter, missing the consensus estimate of ($0.41) by $0.14. The business earned $1.94 million during the quarter, compared to the consensus estimate of $1.75 million. CervoMed had a negative trailing twelve-month return on equity of 44.11% and a negative net margin of 118.68%.

Shares of CRVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that CervoMed investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET) and e.l.f. Beauty (ELF).

Company Calendar

Last Earnings
11/12/2024
Today
1/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:CRVO
Previous Symbol
NASDAQ:CRVO
Employees
4
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$42.00
High Stock Price Target
$63.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+1,702.6%
Consensus Rating
Hold
Rating Score (0-4)
2.44
Research Coverage
9 Analysts

Profitability

Net Income
$-2,170,000.00
Net Margins
-118.68%
Pretax Margin
-118.68%

Debt

Sales & Book Value

Annual Sales
$7.14 million
Book Value
$1.30 per share

Miscellaneous

Free Float
3,930,000
Market Cap
$14.38 million
Optionable
Not Optionable
Beta
1.62
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

This page (NASDAQ:CRVO) was last updated on 1/5/2025 by MarketBeat.com Staff
From Our Partners